Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation studyClinical Trial Published on 2023-03-012023-07-10 Journal: British Journal of Clinical Pharmacology [Category] COVID19(2023년), [키워드] COVID-19 medication safety Pharmacodynamics pharmacokinetics Virology. [DOI] 10.1111/bcp.15560 PMC 바로가기 [Article Type] Clinical Trial
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 studyClinical Trial Published on 2023-03-012023-06-12 Journal: Journal of viral hepatitis [Category] B형 간염, [키워드] Antiviral core inhibitor Hepatitis B virus pharmacokinetics phase 1 study. [DOI] 10.1111/jvh.13764 PMC 바로가기 [Article Type] Clinical Trial
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis BArticle Published on 2022-12-012023-06-13 Journal: Antiviral therapy [Category] B형 간염, [키워드] capsid assembly modulator Chronic Hepatitis B core inhibitor core protein allosteric modulator Hepatitis B virus Pharmacodynamics pharmacokinetics Safety. [DOI] 10.1177/13596535221127848 PMC 바로가기
Pharmaceutics for free-ranging wildlife: Case studies to illustrate considerations and future prospectsArticle Published on 2022-11-252023-07-10 Journal: International journal of pharmaceutics [Category] COVID19(2023년), [키워드] delivery dose one health pharmacokinetics tasmanian devil Vaccines Yellow-eyed penguin zoonoses. [DOI] 10.1016/j.ijpharm.2022.122284 PMC 바로가기
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy AdultsArticle Published on 2022-10-182022-11-15 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CL acid administration adverse event affected agent Antiviral assessment AUC C max COVID-19 demonstrated dose doses drug-drug interaction Effect ensitrelvir first-in-human Food Intake geometric increase in Infection inhibitor Japanese mild in severity MOST novel oral dosing P450 participant Participants participants with SARS-CoV-2 pharmacokinetics phase 1 study Placebo plasma proportionality protease Protease inhibitor protease inhibitor. Randomized reduced resolved Safety SARS-CoV-2 selective single dose substrate T max Tolerability Treatment viral replication [DOI] 10.1128/aac.00632-22 PMC 바로가기
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentArticle Published on 2022-10-012022-11-15 Journal: Clinical Pharmacology and Therapeutics [Category] 치료제, [키워드] 24 hour adjusted Administered adverse event adverse outcome assessments Chronic kidney disease clearance coronavirus disease COVID-19 decrease dose dose reduction Effect eliminated evaluated exhibited geometric geometric mean ratio glomerular filtration rate group increased risk kidney laboratory measurements Mild mild in severity moderate Nirmatrelvir oral participant Patient patients with moderate pharmacokinetics Phase I plasma plasma concentration positively correlated progression reducing renal renal function renal impairment risk Ritonavir severe disease severe renal impairment systemic Tolerability vital signs [DOI] 10.1002/cpt.2688 PMC 바로가기
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapyClinical Trial Published on 2022-10-012023-06-13 Journal: Journal of hepatology [Category] B형 간염, [키워드] Antisense oligonucleotide Chronic Hepatitis B GSK3389404 HBeAg HBsAg pharmacokinetics Safety Virological response. [DOI] 10.1016/j.jhep.2022.05.031 PMC 바로가기 [Article Type] Clinical Trial
Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?Article Published on 2022-09-172022-11-15 Journal: International Journal of Molecular Sciences [Category] SARS, 유전자 메커니즘, 진단, [키워드] adverse effects Antigen complex conventional vaccines COVID-19 COVID-19 mRNA vaccine Dice drug Effect emergency condition Evidence implication mechanism of action mRNA mRNA vaccine mRNA vaccines Pharmacodynamics pharmacokinetic pharmacokinetics Pharmacology representing resulting S protein Safe Safety Safety assessment SARS-CoV-2 SARS-CoV-2 S protein Spike protein spike protein. the SARS-CoV-2 took place translation undergo understanding vaccination [DOI] 10.3390/ijms231810881 PMC 바로가기
Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trialRandomized Controlled Trial Published on 2022-09-052022-10-05 Journal: Critical Care [Category] 임상, [키워드] Acute kidney injury Adequate Adult patient antibiotic Antibiotics clinical Clinical decision support clinical trial control group COVID-19 pandemic Critically ill patient critically ill patients data-driven dose Efficacy eligible Endpoint EudraCT European evaluate faster feasibility feasible for inclusion ICU implementation IMPROVE incidence Inclusion increased mortality Infection intervention group Lactate Mortality Netherland not significantly different outcome patients personalised pharmacokinetic pharmacokinetics Primary outcome randomisation randomised Registered renal right Safe Sepsis Septic shock significantly Support Therapeutic Drug Monitoring Therapeutic drug monitoring. Trial was obtained [DOI] 10.1186/s13054-022-04098-7 PMC 바로가기 [Article Type] Randomized Controlled Trial
Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinoloneResearch article Published on 2022-09-012022-10-05 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료기술, 치료제, [키워드] A549 activity acute respiratory syndrome addition Analysis AUC binding binding affinity Bioinformatics analysis candidate caused Cell cell line clinical investigation Colon conducted coronavirus Coronavirus disease 2019 COVID-19 COVID-19 (Coronavirus disease 2019) COVID-19 infections dataset drug drug target effector memory Efficacy evaluated exhibited FIVE gene signature global pandemic human lung IC50 identification immune immunomodulation immunomodulatory immunosuppressive in vitro in vivo Inflammation Inflammatory Lungs peak plasma concentration pharmacokinetics positive-sense RNA virus respiratory infection SARS-CoV-2 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) SARS-CoV-2 drug SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 pathogenesis SARS-CoV-2-infected patient suggested T cell therapeutic options therapeutic potential therapy threat transcriptomic translation translational vaccine candidates value [DOI] 10.1016/j.compbiomed.2022.105814 [Article Type] Research article